A new treatment for mutant Ras multiple myeloma using a specialized drug conjugate
A novel monobody-drug conjugate to treat mutant Ras multiple myeloma
This study is testing a new treatment for patients with a tough type of cancer called mutant Ras multiple myeloma, using a special drug that targets cancer cells to help improve their chances of recovery.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tezcat Laboratories LLC NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11260526 on NIH RePORTER |
What this research studies
This research focuses on developing a novel biologic treatment for patients with mutant Ras multiple myeloma, a challenging and often resistant form of cancer. The approach utilizes a unique monobody-drug conjugate that targets cancer cells displaying high levels of macropinocytosis, allowing for effective delivery of a cytotoxic agent. The research includes preclinical studies to assess the drug's effectiveness and safety, with plans for further development leading to potential FDA approval. Patients may benefit from a new treatment option that could improve outcomes for this difficult-to-treat cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with mutant Ras multiple myeloma who have experienced treatment resistance.
Not a fit: Patients without mutant Ras mutations or those with early-stage multiple myeloma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with mutant Ras multiple myeloma.
How similar studies have performed: Other research has shown promising results with similar biologic approaches in treating resistant cancers, indicating potential for success in this area.
Where this research is happening
New Haven, United States
- Tezcat Laboratories LLC — New Haven, United States (Active)
Researchers
- Principal investigator: Ramirez, Craig Patrick — Tezcat Laboratories LLC
- Study coordinator: Ramirez, Craig Patrick
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.